§ 01 · Implementation guide
Every step has named owners on both sides and ends with a written record.
STEP 01
Introductory session
Twenty minutes on your pathway, with your clinical, pharmacy and quality leads.
STEP 02
Scoping
Protocols, formulary, governance, systems and the people who will use Daleel.
STEP 03
Configuration
Your protocols, preferences, tumour board rule and exception route, set and documented.
STEP 04
Local validation
Your clinicians write cases and expected results before they see the output. Performance reported per rule.
STEP 05
Go live
Integration switched on for an agreed scope, with named owners on both sides.
STEP 06
Review cycle
Rule updates, declared changes and an agreed review of every exception.
§ 02 · Integration documentation
Detailed documents are shared with each hospital under a mutual confidentiality agreement.
Document
Integration overview
How Daleel Verify connects through FHIR R4 and CDS Hooks, and what each hospital system sends.
Shared with hospitals on request
Document
Interface specification
The documented interfaces, resources and codes, with request and response examples.
Shared with hospitals on request
Document
HL7 v2 mapping
How orders, laboratory results and admissions are read from established systems.
Shared with hospitals on request
Document
Security and hosting pack
Architecture, hosting inside the Kingdom, access control, audit and data protection.
Shared with hospitals on request
§ 03 · Clinical briefs
Each brief is reviewed by our clinical pharmacology specialists before it is shared.
Clinical brief
Breast cancer pathway
The regimens, eligibility criteria and trials behind Daleel Verify Mastos.
Shared with hospitals on request
Clinical brief
Completeness and safety
Why a blank field is never read as normal, and what the gate checks.
Shared with hospitals on request
Clinical brief
Pharmacogenomics in oncology
DPYD, CYP2D6 and the other genes that change treatment and dose.
Shared with hospitals on request
Clinical brief
Prior authorisation in oncology
What a complete request contains, and how it is assembled before submission.
Shared with hospitals on request
§ 04 · Glossary
Plain definitions of the clinical and technical terms used across this website.
§ 05 · Frequently asked questions
If yours is not here, ask us directly.
No. It applies written clinical rules, each shown with its source and version. No dose is produced by a model.
No. The system prepares and the clinician decides. Every decision is recorded with its reason.
The check is reported as not evaluated and automated release stays locked until the data is recorded.
Yes. Protocols, formulary, governance and tumour board rules are configured for each hospital, with your preferences shown beside the evidence.
Systems that exchange FHIR R4, and established systems through HL7 v2, scoped with each integration team.
In a dedicated environment inside the Kingdom, so that no data leaves Saudi Arabia.
Breast cancer first, through Daleel Verify Mastos. The same architecture carries lung, colorectal, prostate, lymphoma, leukaemia and myeloma pathways.
With a twenty minute introductory session. Contact us and we will shape it around your pathway.
Interface specification, HL7 v2 mapping and the security and hosting pack, shared under a mutual confidentiality agreement.